Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice

Table 1

Patients’ baseline characteristics (𝑛=84).

Characteristics (𝑛 (%))	𝑛=84
Median age (years)	70 (range 50–84)
Sex
Male	73 (86.9)
Female	11 (13.1)
ECOG PS*
0	2 (2.4)
1	40 (47.6)
2	35 (41.7)
3	7 (8.3)
Stage
IIIB	2 (2.4)
IV	82 (97.6)
Histology
Squamous cell carcinoma	47 (56.0)
Adenocarcinoma	20 (23.8)
NSCLC (NOS)	13 (15.5)
Large cell carcinoma	2 (2.4)
Adeno- and Squamous cell carcinoma	2 (2.4)
Prior lines of chemotherapy
One	34 (40.5)
Two	36 (42.9)
Three	12 (14.3)
Four	1 (1.2)
Five	1 (1.2)
Smoking status at time of starting of erlotinib
Never smoker	20 (23.8)
Current or former smoker	64 (76.2)
EGFR mutation status
Positive	4 (4.8)
Negative	20 (23.8)
Unknown	60 (71.4)

ECOG PS*: Eastern Cooperative Oncology Group (ECOG) performance status.
NOS: not otherwise specified.